VJHemOnc Podcast

In this insightful discussion, Amer Zeidan from Yale and Rena Buckstein from Sunnybrook share their expert views on treating lower-risk myelodysplastic syndromes (MDS). They highlight the importance of accurate diagnosis with bone marrow examinations and prognostic tools. Guillermo Garcia-Manero from MD Anderson dives into innovative treatments like erythropoiesis-stimulating agents and Luspatercept, while Andrew Brunner emphasizes the complexities of dosing. They advocate for improved strategies and collaboration to enhance patient care and outcomes.

Guest Mohamad Mohty discusses updates on BCMA-targeting bispecific antibodies for multiple myeloma from EHA & ASCO 2024. Topics include MagnetisMM-3 trial data on elranatamab, real-world findings, step-up dosing of teclistamab, MAIC comparison of linvoseltamab with teclistamab, and sequencing of bispecific antibodies with CAR T-cells.

Experts Toby Eyre and Lydia Scarfò discuss the latest updates in CLL treatment, including BTK and BCL2 inhibitor combinations, BTK degraders, and the role of epcoritamab in Richter’s transformation. They explore the trade-off between toxicity and efficacy, potential sequencing strategies, and promising results in heavily pretreated CLL patients, offering insights on future treatments and clinical trials.

Experts Mario Nuvolone, Vaishali Sanchorawala, and Patrick Hagen discuss the critical importance of early diagnosis in AL amyloidosis, ongoing clinical trials like Venetoclax and Exazomib, patient selection for SCT, and challenges in managing relapsed refractory amyloidosis.

Experts discuss novel agents like luspatercept and imetelstat for LR-MDS post ESA failure. They explore HMA use, future trials, and early intervention benefits for patients, shedding light on changing treatment landscapes and improving QoL.

Hematologist Naveen Pemmaraju discusses BPDCN treatment, focusing on CD123-targeting agents like Tagraxofusp. The guests emphasize the importance of early diagnosis, CNS involvement, and tailored strategies for treating adolescents and young adults with this aggressive disease.

Dr. Anna Sureda, an expert in CAR-T therapy, discusses the future of CAR-T therapy in lymphoma and the risk of secondary malignancies. Dr. Manali Kamdar provides an overview of CAR-T products and bispecific antibodies in large B-cell lymphoma, focusing on optimal sequencing for these agents to enhance efficacy.

Experts Ola Landgren, Suzanne Lentzsch, Thomas Martin, and Suzanne Trudel discuss bone disease treatment in myeloma, updates with isatuximab and belantamab mafodotin, and the value of measurable residual disease (MRD) in clinical trials at the iwMyeloma 2024 session. Topics include bisphosphonates, sequencing strategies, drug approval, and the importance of data-sharing in myeloma research.

Experts Mary Frances McMullin and Claire Harrison discuss strategies to manage anemia in myelofibrosis, explore emerging trials in the UK for MPN patients, and touch upon approaches for young patients with MPNs. Topics include combination treatments, ongoing trials, LSD1 inhibitors, and the use of Nivita Mandolin for suboptimal responders.

Experts Mohamad Mohty, Ernst Holler, and Florent Malard share insights on treating GvHD post stem cell transplant, discussing new therapies and the impact of the gut microbiome. Topics include novel agents like ruxolitinib, the role of antibiotics on gut health, benefits of FMT in refractory disorders, and the link between bacterial antigens and transplant outcomes.